Author(s):
Maninder Kour, Vinodini NA, Naynatara Arun Kumar, Bhagyalakshmi K
Email(s):
vinodini.na@manipal.edu
DOI:
10.52711/0974-360X.2026.00055 
Address:
Maninder Kour1, Vinodini NA2*, Naynatara Arun Kumar2, Bhagyalakshmi K2
1Department of Physiology, Oxford Medical College Hospital and Research Centre Bangalore, Karnataka 562107.
2Department Of Physiology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 1,
Year - 2026
ABSTRACT:
Background: Breast cancer is the most common cancer among women globally. It is known that around two-third of patients diagnosed with breast cancers are categorized as hormone dependent cancer. Epidemiological and investigational supports allude that estrogen in the etiology of breast cancer. Most established risk factors for breast cancer in humans probably act through hormone-related pathways, and increased concentrations of circulating estrogens have been found to be strongly associated with increased risk for breast cancer in postmenopausal women. Objectives: The present study is designed to find out the effect of Vitex agnus castus, a herbal extract and anti-prolactin and antigrowth hormone therapy on serum estrogen level in N methyl nitrosurea (MNU) induced SD rats. Materials and Methods: The rats were divided into 6 groups. Control group, Tumor induced group, hyper prolactemia group, cabergoline, octreotide alone and in combination followed by tumor induction and pre, post vitex angus treated group. Results: The study results showed significantly (p<0.001) elevated estrogen levels in tumour induced (II), hyperprolactinemia (III) IVA, IVB VA, VB,VI, compared to group I and on the other hand the pretreated plant extract showed a reduction in the estrogen level compared to post treated. Conclusion: Vitex Agnus is a good therapeutic agent in the treatment of tumorigenesis and prior to the tumour induction gives more beneficial than the post treated
Cite this article:
Maninder Kour, Vinodini NA, Naynatara Arun Kumar, Bhagyalakshmi K. Effect of Vitex Agnus Hydro Alcoholic Extract and Anti Prolactin and Antigrowth Hormone Therapy on Serum Estrogen Level in MNU Induced Tumorigenic SD Rats. Research Journal of Pharmacy and Technology. 2026;19(1):377-1. doi: 10.52711/0974-360X.2026.00055
Cite(Electronic):
Maninder Kour, Vinodini NA, Naynatara Arun Kumar, Bhagyalakshmi K. Effect of Vitex Agnus Hydro Alcoholic Extract and Anti Prolactin and Antigrowth Hormone Therapy on Serum Estrogen Level in MNU Induced Tumorigenic SD Rats. Research Journal of Pharmacy and Technology. 2026;19(1):377-1. doi: 10.52711/0974-360X.2026.00055 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-1-55
REFERENCES:
1. Nidhi Hariramani, Sivaraman Jayanthi. A Systematic Review of Intrinsic Factors and its Influence in Breast Cancer. Research J. Pharm. and Tech. 2018; 11(8): 3543-3546. doi: 10.5958/0974-360X.2018.00654.6
2. van Erkelens A, Derks L, Sie AS, Egbers L, Woldringh G, Prins JB, Manders P, Hoogerbrugge N. Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age. J Genet Couns. 2017; 26(4): 785–791.
3. Dossus L, Benusiglio PR. Lobular breast cancer: incidence and genetic and nongenetic risk factors. Breast Cancer Res. 2015; 17: 37.
4. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102: 1555–1577.
5. Clark JH, Shrader WT, O’Malley BW. Mechanisms of action of steroid hormones. In: Wilson JD, Foster DW, editors. Textbook of Endocrinology. New York: Saunders; 1992. p. 35–90.
6. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogens. Endocr Rev. 1994; 15: 275–300.
7. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996; 10: 615–624.
8. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell. 1995; 83: 851–857.
9. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001; 61: 2537-2541.
10. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, et al. Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer. J Natl Cancer Inst. 2003; 95(5): 353–361.
11. Asaad RA, Abdullah SS. Breast Cancer Subtypes (BCSs) Classification according to Hormone Receptor Status: Identification of patients at High Risk in Jableh-Syria. Res J Pharm Technol. 2018;11(8):3703-3710.
12. Russo JI, Russo HR. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 2006; 102(1–5): 89-96.
13. Dhania Novitasari, Riris Istighfari Jenie, Febri Wulandari, Rohmad Yudi Utomo, Dyaningtyas Dewi Pamungkas Putri, Jun-ya Kato, Edy Meiyanto. Curcumin-like structure (CCA-1.1) induces permanent mitotic arrest (Senescence) on Triple-negative breast cancer (TNBC) cells, 4T1. Res J Pharm Technol. 2021; 14(8): 4375-2. doi: 10.52711/0974-360X.2021.00760
14. Hanaa H. Ahmed, Hadeer A. Aglan, Ghada H. Elsayed, Hebatallah G. Hafez, Emad F. Eskander. Quercetin Offers Chemopreventive Potential against Breast Cancer by Targeting a Network of Signalling Pathways. doi: 10.52711/0974-360X.2021.00499
15. Muhammad Isrul, Risky Juliansyah, Ahmad Saleh, Wa Ode Yuliastri, Jastria Pusmarani, Himaniarwati, Wa Ode Wahyuni Maulidina. Phytochemical Analysis, Standardization and Cytotoxic Activity of Curcuma aureginosa Extract in Human Breast Cancer (MCF-7) Cell Line. Research J. Pharm. and Tech. 2019; 12(4): 1967-1973. doi: 10.5958/0974-360X.2019.00329.9
16. Ohyama K, Akaike T, Hirobe C, Yamakawa T. Cytotoxicity and apoptotic inducibility of Vitex agnus-castus fruit extract in cultured human normal and cancer cells and effect on growth. Biol Pharm Bull. 2003; 26(1): 10–18.
17. McCormick DL, Adamowski CB, Fiks A, et al. Lifetime Dose Response Relationships for Mammary Tumor Induction by a Single Administration of N-Methyl-N-nitrosourea. Cancer Res. 1981; 41: 1690–1694.
18. Airo T, Yen-chang L, Hisanori M, Tomo S, Uehara N, Takashi Y, Katsuhiko Y. Animal Models of N-Methyl-N-nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials. Int J Exp Clin Pathophysiol Drug Res. 2011; 25(1): 11-22.
19. Punna Venkateshwarlu, Mehul M. Patel. A Review: Method Development Validation and Degradation Studies of some Anticancer Drugs. Res J Pharm Technol. 2021; 14(10): 5443-8. doi: 10.52711/0974-360X.2021.00949
20. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003; 24: 1–27.
21. Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat. 1989; 14: 289–298.
22. Anu Singh, Purnima Bharati, Vinita Singh, Ratna Chowdhary. An Immunohistochemical Study to assess the Expression of Estrogen and Progesterone Receptor in Endometrial hyperplasia and Endometrial carcinoma compared to normal Endometrium: A Prospective Pathological Study. . Res J Pharm Technol. 2024; 17(2): 491-5. doi: 10.52711/0974-360X.2024.00076
23. Remal Abdulaziz Asaad. Hormone Receptor Status and its Relation to C-Reactive Protein and other Prognostic factors in Breast Cancer in Jableh- Syria. Research J. Pharm. and Tech. 2017; 10(9): 3003-3010. doi: 10.5958/0974-360X.2017.00532.7
24. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996;10:615–624.
25. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell. 1995;83:851–857.
26. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001; 61: 2537–2542.
27. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, et al. Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer. J Natl Cancer Inst. 2003; 95(5): 353–361.
28. Syam M, Ahmad B, Siddig I, Adel S. In vitro ultramorphological assessment of apoptosis on CEMss induced by linoleic acid-rich fraction from Typhonium flagelliforme tuber. Evid Based Complement Alternat Med. 2011; 12.
29. Bharti Ahirwar, Dheeraj Ahirwar. In vivo and in vitro investigation of cytotoxic and antitumor activities of polyphenolic leaf extract of Hibiscus sabdariffa against, breast cancer cell lines. Research J. Pharm. and Tech. 2019; 13(2): 615-620. doi: 10.5958/0974-360X.2020.00116.X
30. N. Habeela Jainab,, M. K. Mohan Maruga Raja. In Silico Molecular Docking Studies on the Chemical Constituents of Clerodendrum phlomidis for its Cytotoxic Potential against Breast Cancer Markers. Research J. Pharm. and Tech. 2018; 11(4): 1612-1618. doi: 10.5958/0974-360X.2018.00300.1
31. Raghad J. Fayyad, Alaa Naseer Mohammed Ali, Noor T. Hamdan. The Specific Anti-cancerous Mechanisms Suggesting Spirulina Alga as a Promising breast Cancer Fighter. Research Journal of Pharmacy and Technology. 2021; 14(10): 5599-2. doi: 10.52711/0974-360X.2021.00974
32. Merz PG, Gorkow C, Schrodter A, Rietbrock S, Sieder C, Loew D, Dericks-Tan JS, Taubert HD. The effects of a special Agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes. 1996; 104: 447–453.
33. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993; 15(1): 17–35.
34. Carmichael AR. Can Vitex agnus-castus be used for the treatment of mastalgia? What is the current evidence? Evid Based Complement Alternat Med. 2008; 5(3): 247–250.
35. Bounous G, Gervais F, Amer V, Batist G, Gold P. The influence of dietary whey protein on tissue glutathione and the diseases of aging. Clin Invest Med. 1989; 12: 343–349.